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O B J E C T I V E S We sought to assess the prognostic value and risk classiﬁcation improvement using
contemporary single-photon emission computed tomography myocardial perfusion imaging (SPECT-
MPI) to predict all-cause mortality.
B A C KG ROUND Myocardial perfusion is a strong estimator of prognosis. Evidence published to
date has not established the added prognostic value of SPECT-MPI nor deﬁned an approach to detect
improve classiﬁcation of risk in women from a developing nation.
METHOD S A total of 2,225 women referred for SPECT-MPI were followed by a mean period of 3.7
1.4 years. SPECT-MPI results were classiﬁed as abnormal on the presence of any perfusion defect.
Abnormal scans were further classiﬁed as with mild/moderate reversible, severe reversible, partial
reversible, or ﬁxed perfusion defects. Risk estimates for incident mortality were categorized as1%/year,
1% to 2%/year, and 2%/year using Cox proportional hazard models. Risk-adjusted models incorpo-
rated clinical risk factors, left ventricular ejection fraction (LVEF), and perfusion variables.
R E S U L T S All-cause death occurred in 139 patients. SPECT-MPI signiﬁcantly risk stratiﬁed the
population; patients with abnormal scans had signiﬁcantly higher death rates compared with patients
with normal scans, 13.1% versus 4.0%, respectively (p  0.001). Cox analysis demonstrated that after
adjusting for clinical risk factors and LVEF, SPECT-MPI improved the model discrimination (integrated
discrimination index  0.009; p  0.02), added signiﬁcant incremental prognostic information (global
chi-square increased from 87.7 to 127.1; p  0.0001), and improved risk prediction (net reclassiﬁcation
improvement  0.12; p  0.005).
CONC L U S I O N S SPECT-MPI added signiﬁcant incremental prognostic information to clinical and
left ventricular functional variables while enhancing the ability to classify this Brazilian female population
into low- and high-risk categories of all-cause mortality. (J Am Coll Cardiol Img 2011;4:880–8) © 2011
by the American College of Cardiology Foundation
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881nterest and emphasis on research concerning
women and heart disease has grown substantially
with increasing recognition of the importance of
heart disease related to the female sex (1). How-
ver, a concerning gap in the knowledge, under-
tanding, and general awareness of ischemic heart
isease (IHD) in women still remains. Evidence-
ased guidelines for the prevention and treatment
f IHD rely largely on the results of randomized
linical trials where women are usually underrepre-
ented (2–4).
See page 889
The ability of single-photon emission computed
tomography myocardial perfusion imaging
(SPECT-MPI) to evaluate myocardial perfusion
and left ventricular ejection fraction (LVEF) is well
documented (5,6). Previous studies have deter-
mined the incremental prognostic value of myocar-
dial perfusion and LVEF data to predict adverse
outcomes in several subgroups, using different stress
methods and radionuclide tracers (7–11). Most
studies that evaluated the prognostic value of
SPECT-MPI in women collected data before the
year 2000 (12–14). In the following years, impor-
tant changes in IHD treatment were introduced in
clinical practice (15,16).
The spectrum of IHD varies across different
ethnic populations and environments. Statistics
from the World Health Organization reveal that
IHD is the leading cause of death worldwide for
adult women. Brazil, like other developing coun-
tries, has a highly variable racial, variable ethni-
cal, and socioeconomically diverse population
with a projected 40% increase in IHD mortality
in young-to-middle-aged individuals (17). This
study assessed the contemporary prognostic value
of SPECT-MPI in women of a developing na-
tion, with all-cause mortality as the main adverse
outcome. We also evaluated the extent to which
adding myocardial perfusion to a model based on
traditional risk factors and LVEF correctly re-
classified subjects in terms of risk of future
all-cause mortality events.
M E T H O D S
Study population. The study cohort comprised
,427 consecutive female patients between 55 and
5 years of age who underwent SPECT-MPI
etween March 2004 and October 2007 at Quanta
iagnostico Nuclear, Curitiba, Brazil. Reasons for LPECT-MPI referral included chest pain evalua-
ion, systolic dysfunction investigation, surveillance
f known IHD, diabetes mellitus workup, pre-
perative workup, and evaluation due to abnormal
r inconclusive treadmill test. Clinical data were
ollected prospectively at study entrance. The only
re-specified exclusion criteria were sex and age,
ince males and older individuals have distinct IHD
isk patterns and were out of the scope of the
resent investigation. The study was approved by
he institutional review board, and all participants
ave written informed consent.
Imaging acquisition protocol. All participants were
ubmitted to stress (exercise or pharmacological
rotocols) and rest studies after intravenous injec-
ion of 20 to 25 mCi of 99mTc-sestamibi, based on
atient weight. Conventional image protocol acqui-
ition using standard energy windows for
99mTc in dual-head gamma cameras with a
low-energy all-purpose collimator was
performed. No attenuation or scatter cor-
rection was used. Images started 30 to 60
min after injection in the resting state and
15 to 30 min after injection at peak stress. An
electrocardiography-gated SPECT acqui-
sition was also performed.
Image interpretation. Semiquantitative vi-
ual interpretation of SPECT-MPI was
erformed by consensus of 2 experienced,
oard-certified observers using short-axis
nd vertical long-axis slices, divided into
7 standard segments for each patient
18). Each segment was scored based on
he tracer uptake as: 0, normal; 1, mildly
educed; 2, moderately reduced; 3, severely
educed; and 4, absent tracer uptake in rest
nd stress images. A summed rest score (SRS) and
ummed stress score (SSS) were obtained by adding
he scores of the 17 segments of the rest and stress
mages, respectively. The summed difference score
SDS) was determined by subtracting the SRS from
he SSS. Studies were classified as normal (SSS4)
r abnormal (SSS 4). Abnormal studies were
urther classified as having mild-to-moderate com-
lete reversible perfusion defects (SSS  4 to 12
nd SRS 4), severe complete reversible perfusion
efects (SSS 13 and SRS 4), partial reversible
erfusion defects (SSS4, SRS4, and SDS2),
r only fixed perfusion defects (SSS 4 and
DS 2). The gated images were processed by
uantified gated SPECT software (QGS, Cedars-
inai, Los Angeles, California) to obtain post-stress
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882Clinical data and patient follow-up. Clinical data in-
luding age, diabetes, hypertension, hyperlipidemia,
ody mass index, smoking status, symptoms, family
istory of premature IHD, and prior history of
nown IHD (prior myocardial infarction, revascu-
arization, or IHD confirmed by coronary angiog-
aphy) were collected prospectively at study en-
rance, before the SPECT-MPI study.
Follow-up was performed by blinded scripted
elephone interviews. A minimum of 3 telephone
ontact attempts to patients and family members
ere made. If interview attempts failed, referring
hysicians were contacted, and the last office visit
fter the SPECT-MPI study was used as the
ensoring date.
The only outcome was all-cause mortality, which
as confirmed by death certificate in government
ecords in all cases. Subjects submitted to coronary
evascularization after the SPECT-MPI were cen-
ored at the time of the procedure. Subjects not
onfirmed to be deceased by death certificate and
ithout any follow-up information were considered
ost to follow-up.
Statistical analysis. Statistical analyses were per-
formed using Stata Statistical Software, release 11
(StataCorp, College Station, Texas). Comparisons
between patient groups were performed using
Kruskal-Wallis, chi-square, and ANOVA tests.
Cumulative mortality rate curves were calculated
using the Kaplan-Meier method and compared by
log-rank test. A p value of 0.05 was considered
statistically significant.
The effect of the myocardial perfusion result by
SPECT-MPI on mortality and the 3-year esti-
mated incident mortality risk were determined us-
ing Cox regression models. Three models were
created in the order in which they would actually be
considered in clinical practice: 1) clinical model;
2) clinical  LVEF model, adding LVEF; and
3) clinical  LVEF  perfusion model, including
SPECT-MPI results. The risk estimates were cat-
egorized as 3%, 3% to 6%, and 6% risk of
mortality in 3 years, corresponding to low, interme-
diate, and high risk (1%, 1% to 2%, 2% event
rate per year).
Discrimination was assessed comparing the areas
under the receiver-operator characteristics curves of
each model using the DeLong method for corre-
lated curves (19). We also calculated the integrated
discrimination index (IDI) and the net reclassifica-
tion improvement (NRI) between models following
the methodology of Pencina et al. (20,21). vIn an attempt to project potential misleading
results due to the loss of follow-up patients missing
data, we conducted a sensitivity analysis using a
multiple imputation for missing data approach
(22,23).
R E S U L T S
Clinical characteristics and SPECT-MPI results. The
study population included 2,427 women. Follow-up
information was not available for 202 individuals
(8.3%), leaving a final study cohort of 2,225 partic-
ipants. The final cohort mean population age was
64.5  5.6 years, with a mean LVEF of 64.4 
10.9%. Four hundred and fifty (20.2%) had past
history of known IHD, with prior myocardial
infarction in 182 (8.2%). The stress testing method
was treadmill exercise in 1,626 (73.1%) and phar-
macological in 599 (26.9%) patients. Interestingly,
999 (44.9%) participants were asymptomatic and
were referred for SPECT-MPI due to surveillance
of known IHD (18.5%), diabetes mellitus workup
(20.7%), and largely due to abnormal or inconclu-
sive treadmill test (42.7%). Table 1 shows the
baseline clinical characteristics stratified by the
SPECT-MPI result.
From the 548 (24.6%) subjects with abnormal
scans, 443 (80.8%) had complete reversible perfu-
sion defects, 53 (9.7%) had only fixed perfusion
defects, and 52 (9.5%) had partial reversible perfu-
sion defects.
Survival analysis by the presence, severity, and type of
perfusion defects on SPECT-MPI. During the mean
ollow-up period of 3.7  1.4 years, there were 139
eaths with an event rate of 6.2%. Overall survival
as 96.0% and 86.9% among the cohort when
rouped according to the absence or presence of
erfusion defects, respectively (p  0.001) (Fig. 1A).
he unadjusted hazard ratio (HR) for mortality was
.53 (95% confidence interval [CI]: 3.25 to 6.32).
fter adjustment for clinical IHD risk factors and
VEF, the multivariable model showed that the
resence of any perfusion defect (SSS 4) was an
ndependent predictor of mortality (HR: 3.02, 95%
I: 2.06 to 4.44).
Considering subgroups with abnormal SPECT-
PI results stratified by the type and extent of
erfusion defects, survival rates and adjusted HRs
re presented in Tables 1 and 2. Adjusted survival
nalysis curves are shown in Figure 1B.
Conventional risk factors, LVEF, and myocardial perfu-
sion defect as predictors of all-cause mortality. Uni-
ariate analysis demonstrated that known IHD
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883(HR: 1.65, 95% CI: 1.14 to 2.40) and older age
(HR: 1.06, 95% CI: 1.03 to 1.10) were the only
significant clinical variables for the prediction of
death. Lower LVEF and presence of any perfusion
defect were also highly predictive of death, with
HRs of 0.95 (95% CI: 0.94 to 0.96) and 4.53 (95%
CI: 3.25 to 6.32), respectively. In multivariate
analysis (Table 2), only older age remained a clinical
predictor of all-cause mortality after inclusion of
LVEF and SPECT-MPI results to the model.
According to a realistic clinical approach, adding
LVEF and SPECT-MPI results to the clinical
model resulted in significant incremental prognostic
information, measured by the improvement in the
global chi-square (Table 2).
Perfusion defects and all-cause mortality discrimina-
tion. Measures of discrimination showed a signifi-
ant improvement with the inclusion of LVEF and
PECT-MPI results to the prediction model. In
ur cohort of patients, the areas under the receiver-
perator characteristic curves for the prediction of
ll-cause death significantly increased with addition
f both variables (Table 2).
Also, the IDI was 0.031 (p  0.001) when
LVEF was added to the clinical model (relative IDI
of 3.7), and 0.009 (p  0.02) when SPECT-MPI
results were added to the clinical  LVEF model
(relative IDI of 0.24).
Perfusion defects and risk category reclassiﬁcation.
The addition of LVEF to the clinical predictive
Table 1. Clinical Characteristics, LVEF, SSS, and SRS, Absolute M
Variable
Normal Mild/Moderate Reversible D
(N  1,677) (N  382)
Age, yrs 64.1 (5.6) 65.5 (5.4)
BMI, kg/m2 27.6 (4.8) 28.4 (5.7)
Hypertension 71.9% 81.3%
Diabetes mellitus 17.5% 28.7%
Hyperlipidemia 57.0% 62.6%
Smoking 10.1% 12.1%
Known IHD 13.3% 33.4%
Symptoms
Typical Angina 6.3% 11.6%
Atypical Angina 46.8% 51.8%
Asymptomatic 46.8% 36.6%
LVEF, % 66.7 (8.5) 60.7 (12.6)
SSS 0.05 (0.4) 6.5 (2.6)
SRS 0.01 (0.2) 0.02 (0.2)
All-cause mortality 67 38
Survival rate 96.0% 89.8%
Values are presented as means (SD), %, or N.
BMI  body mass index; IHD  ischemic heart disease; LVEF  left ventricular
summed rest score.model reclassified 45% of the sample, mostly due todownward reclassification (33.9%) of individuals
that were subsequently free of mortality during
follow-up, achieving an NRI of 0.26 (95% CI: 0.14
to 0.37, p  0.001). The further addition of
SPECT-MPI results reclassified 28% of the sam-
ple, also mostly due to downward reclassification
(17%) of individuals that were subsequently out-
come free. Upward reclassification of patients that
subsequently had a fatal event was achieved in only
1% of the cohort. The NRI for event was 0.03 and
the NRI for non-event was 0.09, achieving an NRI
of 0.12 (95% CI: 0.04 to 0.21, p  0.005).
Cross-tabulations of the 3-year estimated risk and
Kaplan-Meier event rates for the last 2 models are
shown in Table 3.
The risk stratification capacity of the models is
shown in Figure 2. The left panel shows that
including myocardial perfusion to the model with
clinical factors and LVEF places 61% of the overall
population into either the highest or lowest risk
categories, compared with 46% in the clinical model
and 53% in the clinical  LVEF model. With the
addition of the SPECT-MPI results, an additional
8.5% of those who did not experience events were
reclassified as low risk (Fig. 2, right panel) and an
additional 3.6% of those who experience events
were reclassified as high-risk (Fig. 2, center panel)
when compared with the model including clinical
risk factors and LVEF.
Examples of normal and abnormal SPECT-MPI
ality Incidence, and Survival Rate Stratiﬁed by the SPECT-MPI Re
ct Fixed Defect Severe Reversible Defect Partial Reversib
(N  53) (N  61) (N  52
64.6 (5.1) 66.3 (5.5) 66.0 (5.5
27.4 (5.1) 28.5 (5.8) 27.7 (5.7
88.2% 86.7% 85.7%
25.5% 46.7% 26.8%
64.7% 66.7% 64.3%
11.8% 5.0% 19.7%
78.4% 28.3% 76.8%
7.8% 27.6% 12.5%
43.1% 38.0% 35.7%
49.0% 34.5% 51.8%
51.0 (13.1) 50.4 (13.6) 46.0 (13.
10.6 (8.1) 18.8 (6.0) 16.8 (7.8
10.6 (7.9) 0.01 (0.2) 8.1 (6.3)
10 12 12
81.1% 80.3% 78.8%
tion fraction; SPECT  single-photon emission computed tomography; SSS  sumort sults
efe le Defect
p Value)
) 0.0001
) 0.31
0.001
0.001
0.12
0.08
0.001
0.001
9) 0.0001
) 0.0001
0.0001
0.0001
0.0001
ejec med stress score; SRS images from 2 patients with multiple risk factors
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884and atypical angina classified as high risk for
all-cause mortality (2%/year) by the model with
clinical factors and LVEF, but with distinct
outcomes during the follow-up are presented in
Figure 3.
Sensitivity analysis. Although the clinical and
PECT-MPI variables were similar between the
ncluded and lost to follow-up populations, the
Figure 1. Risk-Adjusted Cumulative Incidence of All-Cause Mort
(A) All-cause mortality is shown according to the presence or absen
raphy myocardial perfusion imaging (SPECT-MPI) and (B) according
plete reversible, partial reversible, or only ﬁxed perfusion defects by
Models of All-Cause Mortality
Clinical p Value Clinical  LV
1.07 (1.03–1.10) 0.001 1.07 (1.03–1.
1.74 (1.10–2.75) 0.02 1.47 (0.93–2.
1.55 (1.06–2.25) 0.02 1.21 (0.83–1.
— — 0.95 (0.94–0.
al
sible defects — — —
— — —
ects — — —
fects — — —
27.4 87.7
rve (95% CI) 0.61 (0.56–0.66) 0.69 (0.65–0.
zard ratios with 95% conﬁdence intervals (CI). *p value for the difference between
perfusion models.1.VEF was slightly but significantly higher in
he followed cohort (64.4  10.9% vs. 61.2 
3.4%; p  0.001), and a sensitivity analysis was
conducted. Applying mortality rates of 6.2%, 10%,
50%, and 100% on the lost to follow-up population,
the multivariate HRs variation for abnormal
SPECT, mild/moderate complete reversible perfu-
sion defects, severe complete reversible perfusion
of perfusion defects by single-photon emission computed tomog-
he presence of mild/moderate complete reversible, severe com-
ECT-MPI. Mild/Mod  mild and moderate.
p Value Clinical  LVEF  Perfusion p Value
0.001 1.06 (1.03–1.10) 0.001
0.1 1.57 (0.99–2.50) 0.055
0.3 0.78 (0.51–1.20) 0.27
0.001 0.97 (0.96–0.98) 0.001
1.0
— 2.52 (1.64–3.85) 0.001
— 4.42 (2.07–9.44) 0.001
— 5.29 (2.53–11.03) 0.001
— 6.01(3.08–11.71) 0.001
0.001* 127.1 0.001‡
0.0004* 0.73 (0.68–0.77) 0.02‡
ical and clinical  LVEF models; †p value for the difference between clinical ality
ce
to tTable 2. Multivariate
Variable EF
Age 10)
Smoking 33)
Known IHD 78)
LVEF 96)
SPECT-MPI result Norm
Mild/moderate rever
Fixed defects
Partial reversible def
Severe reversible de
Global chi-square
Area under the ROC cu 74)
Values are presented as ha clin
LVEF and clinical  LVEF 
ppli
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885defects, only fixed perfusion defects, and partial
reversible perfusion defects were 2.96 to 3.01, 2.55
to 2.84, 4.84 to 5.33, 3.10 to 4.46, and 4.16 to 5.13,
Table 3. Three-Year Risk of All-Cause Mortality Predicted by the
3-Year Risk in Clinical  LVEF
Model <3% 3%–6%
3%
Participants 585 67
With events 11 4
Without events 574 63
Kaplan-Meier 3-yr risk (95% CI) 1.6 (0.8–3.0) 1.6 (0.2–10.9)
3%–6%
Participants 236 640
With events 4 29
Without events 232 611
Kaplan-Meier 3-yr risk (95% CI) 1.7 (0.6–4.6) 3.5 (2.3–5.4)
6%
Participants 0 339
With events 0 21
Without events 0 318
Kaplan-Meier 3-yr risk (95% CI) NA 3.8 (2.2–6.6)
Overall
Participants 821 1,046
With events 15 54
Without events 806 992
Kaplan-Meier 3-yr risk (95% CI) 1.6 (0.9–2.8) 3.5 (2.5–4.8)
*The net reclassiﬁcation improvement is 0.12 (95% CI: 0.04 to 0.21, p  0.005)
CI  conﬁdence interval; LVEF  left ventricular ejection fraction; NA  not a
Figure 2. Risk Stratiﬁcation of the Clinical, Clinical  LVEF, andLVEF  left ventricular ejection fraction.respectively. Even in the worst scenario tested, the
log-rank test comparing the cumulative mortality
curves had a p  0.001.
nical  LVEF and Clinical  LVEF  Perfusion Models
3-Year Risk in Clinical  LVEF  Perfusion Model*
>6% Overall Reclassiﬁed Higher Risk Rec
7 272
0 8 4 (50%)
7 264 70 (26.5%)
0 1.5 (0.6–4.0)
142 1,201
26 66 26 (39.4%)
116 1,135 116 (10.2%)
14.2 (9.2–21.7) 4.2 (3.2–5.6)
385 752
44 65 NA
341 687 NA
10.4 (7.6–14.2) 6.9 (5.3–9.2)
534 2,225
70 139 30 (21.6%)
464 2,086 186 (8.9%)
11.1 (8.6–14.2) 4.8 (3.9–5.8)
cable.
ical  LVEF  Perfusion ModelsCli
lassiﬁed Lower Risk
NA
NA
11 (16.7%)
408 (35.9%)
21 (32.3%)
346 (50.4%)
32 (23%)
754 (36.2%)
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886D I S C U S S I O N
Over 80% of cardiovascular deaths occur in low-
and middle-income countries and occur almost
equally in men and women (17). Although women
with IHD have more adverse outcomes as com-
pared with men (24), physicians still often under-
estimate their IHD prevalence, and studies have
reported a gender bias in the management of IHD,
even in contemporary practice (2,3). With the new
paradigms where MPI may be used to guide IHD
patient decision making regarding target interven-
tion or clinical treatment, the prognostic implica-
tion of different types and severity of perfusion
defects must be completely defined in the previously
underrepresented female population (25,26).
Our results show that women with abnormal
SPECT-MPI results had a 3.02 times higher inci-
dence of all-cause death during the follow-up pe-
f SPECT-MPI
ton emission computed tomography myocardial perfusion
patients with multiple risk factors and atypical angina classiﬁed
se mortality (2%/year) by the clinical  left ventricular ejection
ient with signiﬁcant anteroseptal perfusion defect (white arrows).
T-MPI results to the model, the patient probability of all-cause
m 2.8% to 4.5%/year, remaining in the higher-risk range of
died after 2.1 years of follow-up. (B) Patient with normal myocar-
ding the SPECT-MPI results to the model, the patient was reclassi-
%/year) to low risk (0.9%/year) and survived after 3.5 years ofriod, when compared with women with normal rresults. Additionally, by assessing the extent and
severity of defect size and its degree of reversibility,
SPECT-MPI provided a continuum of risk strati-
fication (12,14).
In developed nations, SPECT-MPI has been
shown to have a powerful predictive value regarding
cardiac death, myocardial infarct, or the need of
coronary revascularization in a multitude of clinical
studies with more than 15,000 women (27) and has
also been shown to risk stratify and add incremental
prognostic value to clinical and exercise variables
(28). Elhendy et al. (29) evaluated SPECT-MPI
for predicting all-cause mortality in 503 women
with known or suspected coronary IHD. The an-
nual mortality rate was 1.4% with normal and 4%
with abnormal perfusion (p  0.01) during a
edian follow-up of 3.5 years. Comparatively, our
esults show an annualized mortality rate of 0.94%
n patients with normal SPECT-MPI and 7.2% in
atients with severe complete reversible perfusion
efects during a similar follow-up period, indicating
slightly lower death rate in patients with normal
yocardial perfusion, but a higher rate in patients
ith severe defects.
Finally, the presence of myocardial perfusion
efect was incremental and led to a more refined
stimation of mortality risk. An important strength
f a diagnostic test is the number of patients
dentified as having higher and lower risk and,
onsequently, becoming eligible or not to receive
ifferent therapy (usually more intensive and expen-
ive). Almost 7.5% of the total cohort was reclassi-
ed as high risk and 10.6% as low risk with the
PECT-MPI results. Importantly, 54% of the
vents (75 of 139) occurred in individuals classified
s high risk, and 73% (1,624 of 2,086) of the
atients classified as low or intermediate risk by
he final model were alive at the last follow-up.
nspection of relative contribution of correct
eclassification for event or non-event also reveals
mportant strengths and weakness of SPECT-
PI. When adding myocardial perfusion data to
he model, the NRI for events was 0.03, whereas
he NRI for non-events was 0.09, suggesting that
PECT-MPI may identify more individuals who
o not experience events than individuals who do.
nother metric of a test’s utility is the ability to
eparate individuals into more clinically relevant
isk categories. When myocardial perfusion was
dded to the final model, almost 16% of the
ntermediate-risk group were reclassified as highFigure 3. Examples o
Examples of single-pho
images (SPECT-MPI) of
as high risk for all-cau
fraction model. (A) Pat
After adding the SPEC
mortality increased fro
2%/year. The patient
dial perfusion. After ad
ﬁed from high risk (2.3isk, whereas 22.6% were reclassified as low risk,
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887where treatment strategies may be better defined
(Fig. 2).
Radiation dose of cardiac imaging is always a
concern, and therefore, the ALARA (“As Low
As Reasonably Achievable”) principle should be
applied. Our standard myocardial perfusion im-
aging protocol has an effective dose near 10 mSv.
Approximately 8.3% of the initial population was
lost to follow-up. Sensitivity analysis concluded that
inclusion of data from this missing group would not
have affected the overall study results.
This study has some other limitations. Results
are based on a female population between 55 and
75 years old referred to cardiac SPECT-MPI
who may have more severe disease than a nonre-
ferral population. A final consensus of 2 readers
was used as the final SPECT-MPI result instead
of blinded interpretations. Also, the study was
not designed to evaluate management strategies,post-stress left ventricular ejection
1
1
1
Coll Cardiol 2003;However, the performance of angioplasty or sur-
gical coronary revascularization may have altered
the total mortality of the population, despite
censoring at the time of the procedure when the
information was available.
C O N C L U S I O N S
SPECT-MPI added significant incremental prog-
nostic information to clinical and left ventricular
functional variables. Myocardial perfusion data also
substantially enhances the ability to classify this
Brazilian female population with known or sus-
pected IHD into low- and high-risk categories of
all-cause mortality.
Reprint requests and correspondence: Dr. Mario Sergio
ulio Cerci, Quanta Diagno´stico Nuclear, Rua Almirante
amadaré, 1000, Curitiba (PR), CEP 80045-170, Brazil.and no conclusions can be made in this regard. E-mail: cerci@hospitalcoracao.com.br.R E F E R E N C E S
1. Shaw LJ, Bairey Merz CN, Pepine
CJ, et al. Insights from the NHLBI-
sponsored Women’s Ischemia Syn-
drome Evaluation (WISE) study: part
I: gender differences in traditional and
novel risk factors, symptom evalua-
tion, and gender-optimized diagnostic
strategies. J Am Coll Cardiol 2006;47:
S4–20.
2. Lee PY, Alexander KP, Hammill BG,
Pasquali SK, Peterson ED. Represen-
tation of elderly persons and women
in published randomized trials of
acute coronary syndromes. JAMA
2001;286:708–13.
3. Melloni C, Berger JS, Wang TY, et al.
Representation of women in random-
ized clinical trials of cardiovascular
disease prevention. Circ Cardiovasc
Qual Outcomes 2010;3:135–42.
4. Mosca L, Banka CL, Benjamin EJ, et
al. Evidence-based guidelines for car-
diovascular disease prevention in
women: 2007 update. Circulation
2007;115:1481–501.
5. Cerqueira MD, Harp GD, Ritchie JL.
Evaluation of myocardial perfusion
and function by single photon emis-
sion computed tomography. Semin
Nucl Med 1987;17:200–13.
6. Germano G, Kiat H, Kavanagh PB, et
al. Automatic quantification of ejec-
tion fraction from gated myocardial
perfusion SPECT. J Nucl Med 1995;
36:2138–47.
7. Sharir T, Germano G, Kavanagh PB,
et al. Incremental prognostic value offraction and volume by gated myocar-
dial perfusion single photon emission
computed tomography. Circulation
1999;100:1035–42.
8. Iskandrian AS, Chae SC, Heo J,
Stanberry CD, Wasserleben V, Cave
V. Independent and incremental
prognostic value of exercise single-
photon emission computed tomo-
graphic (SPECT) thallium imaging in
coronary artery disease. J Am Coll
Cardiol 1993;22:665–70.
9. Hendel RC, Layden JJ, Leppo JA.
Prognostic value of dipyridamole thal-
lium scintigraphy for evaluation of
ischemic heart disease. J Am Coll
Cardiol 1990;15:109–16.
0. Shaw L, Chaitman BR, Hilton TC, et
al. Prognostic value of dipyridamole
thallium-201 imaging in elderly pa-
tients. J Am Coll Cardiol 1992;19:
1390–8.
1. Piccini JP, Starr AZ, Horton JR, et al.
Single-photon emission computed to-
mography myocardial perfusion imag-
ing and the risk of sudden cardiac
death in patients with coronary disease
and left ventricular ejection fraction
35%. J Am Coll Cardiol 2010;56:
206–14.
2. Berman DS, Kang X, Hayes SW, et
al. Adenosine myocardial perfusion
single-photon emission computed to-
mography in women compared with
men. Impact of diabetes mellitus on
incremental prognostic value and ef-
fect on patient management. J Am41:1125–33.13. Marwick TH, Shaw LJ, Lauer MS, et
al. The noninvasive prediction of car-
diac mortality in men and women
with known or suspected coronary ar-
tery disease. Economics of Noninva-
sive Diagnosis (END) Study Group.
Am J Med 1999;106:172–8.
14. Hachamovitch R, Berman DS, Kiat
H, et al. Effective risk stratification
using exercise myocardial perfusion
SPECT in women: gender-related
differences in prognostic nuclear test-
ing. J Am Coll Cardiol 1996;28:
34–44.
15. Smith SC Jr., Allen J, Blair SN, et al.
AHA/ACC guidelines for secondary
prevention for patients with coronary
and other atherosclerotic vascular dis-
ease: 2006 update. J Am Coll Cardiol
2006;47:2130–9.
16. Morice MC, Serruys PW, Sousa JE,
et al. A randomized comparison of a
sirolimus-eluting stent with a stan-
dard stent for coronary revascular-
ization. N Engl J Med 2002;346:
1773– 80.
17. World Health Organization. Cardio-
vascular diseases: World Heart Day
2011. Available at: http://www.
who.int/cardiovascular_diseases/en/.
Accessed July 2, 2011.
18. Cerqueira MD, Weissman NJ, Dilsi-
zian V, et al. Standardized myocardial
segmentation and nomenclature for
tomographic imaging of the heart: a
statement for healthcare professionals
from the Cardiac Imaging Committee
of the Council on Clinical Cardiology
12
2
2
2
2
2
2
2
2
2
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 8 , 2 0 1 1
A U G U S T 2 0 1 1 : 8 8 0 – 8
Cerci et al.
Ischemic SPECT-MPI Predicts Death in Women
888of the American Heart Association.
Circulation 2002;105:539–42.
9. DeLong ER, DeLong DM, Clarke-
Pearson DL. Comparing the areas
under two or more correlated receiver
operating characteristic curves: a non-
parametric approach. Biometrics
1988;44:837–45.
0. Pencina MJ, D’Agostino RB Sr.,
D’Agostino RB Jr., Vasan RS. Evalu-
ating the added predictive ability of a
new marker: from area under the
ROC curve to reclassification and be-
yond. Stat Med 2008;27:157–72, dis-
cussion 207–12.
1. Pencina MJ, D’Agostino RB Sr.,
Steyerberg EW. Extensions of net
reclassification improvement calcula-
tions to measure usefulness of new
biomarkers. Stat Med 2011;30:11–21.
2. Sterne JA, White IR, Carlin JB, et al.
Multiple imputation for missing data
in epidemiological and clinical re-
search: potential and pitfalls. BMJ
2009;338:b2393.
3. Brinkhof MW, Spycher BD, Yi-
annoutsos C, et al. Adjusting mortal-ity for loss to follow-up: analysis of
five ART programmes in sub-Saharan
Africa. PLoS One 2010;5:e14149.
4. Lloyd-Jones D, Adams RJ, Brown
TM, et al. Heart disease and stroke
statistics—2010 update: a report from
the American Heart Association. Cir-
culation 2010;121:e46–215.
5. Shaw LJ, Berman DS, Maron DJ, et
al. Optimal medical therapy with or
without percutaneous coronary inter-
vention to reduce ischemic burden: re-
sults from the Clinical Outcomes Uti-
lizing Revascularization and Aggressive
Drug Evaluation (COURAGE) trial
nuclear substudy. Circulation 2008;
117:1283–91.
6. Wijns W, Kolh P, Danchin N, et al.
Guidelines on myocardial revascular-
ization: the Task Force on Myocardial
Revascularization of the European
Society of Cardiology (ESC) and the
European Association for Cardio-
Thoracic Surgery (EACTS). Eur
Heart J 2010;31:2501–55.
7. Mieres JH, Shaw LJ, Arai A, et al.
Role of noninvasive testing in the
clinical evaluation of women with sus- wpected coronary artery disease: con-
sensus statement from the Cardiac
Imaging Committee, Council on
Clinical Cardiology, and the Cardio-
vascular Imaging and Intervention
Committee, Council on Cardiovascu-
lar Radiology and Intervention,
American Heart Association. Circula-
tion 2005;111:682–96.
8. Shaw LJ, Iskandrian AE. Prognostic
value of gated myocardial perfusion
SPECT. J Nucl Cardiol 2004;11:
171– 85.
9. Elhendy A, Schinkel AF, van Dom-
burg RT, Bax JJ, Valkema R, Polder-
mans D. Prediction of all-cause mor-
tality in women with known or
suspected coronary artery disease by
stress technetium-99m tetrofosmin
myocardial perfusion imaging. Am J
Cardiol 2004;93:450–2.
Key Words: mortality y net
reclassification improvement y
prognosis y SPECT-MPI yomen.
